Commercial LightCycler®-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma
Commercial LightCycler®-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma
复制标题
基于商业 LightCycler® 的实时 PCR 与巢式 PCR 相比，用于定量监测滤泡性淋巴瘤患者的 Bcl-2/IgH 重排
作者：
M. Kornacker;B. Kornacker;C. Schmitt;E. Leo;A. Ho;M. Hensel
14号和18号染色体易位[t(14；18)]用于检测滤泡性淋巴瘤患者微小残留病可以通过套式聚合酶链式反应(PCR)或定量PCR(如LightCycler®分析)进行分析。我们对参加免疫化疗临床研究的28名患者的血液和骨髓样本进行了比较。在42%的样本中，套式聚合酶链式反应可检测到bcl2-IgH重排，但LightCycler®聚合酶链式反应不能。巢式聚合酶链式反应能够显示治疗后骨髓或外周血阳性样本的显著下降。相比之下，用LightCycler®PCR检测到的t(14；18)阳性细胞的下降没有达到统计学意义。大多数患者外周血或骨髓的套式聚合酶链式反应结果为阳性，与淋巴瘤细胞是否有组织学骨髓(BM)浸润没有任何关联。LightCycler®聚合酶链式反应检测结果显示，有淋巴瘤细胞浸润者(1.90 × 10−2)的阳性细胞数明显高于无骨髓浸润者(4.0 8 × 10−5)。从外周血中提取的样本中也出现了类似的趋势。两名患者治疗后t(14；18)阳性与6个月后临床复发相关。此处显示的数据显示，LightCycler®检测t(14；18)的灵敏度低于套式PCR。套式聚合酶链式反应的t(14；18)用于初步治疗后风险分层的有效性必须在更大规模的试验中得到验证。
Translocation of chromosomes 14 and 18 [t(14;18)] for detection of minimal residual disease in follicular lymphoma patients can be analyzed by nested polymerase chain reaction (PCR) or by quantitative PCR like LightCycler®-based assays. We have compared both methods in blood and bone marrow samples of 28 patients enrolled in a clinical study on immunochemotherapy. In 42% of samples, the bcl2–IgH rearrangement was detectable by nested PCR, but not by LightCycler® PCR. Nested PCR was able to reveal a significant drop in positive bone marrow or peripheral blood samples after therapy. In contrast, with LightCycler® PCR, the detected drop in t(14;18)-positive cells did not reach statistical significance. The majority of patients showed positive results with nested PCR of peripheral blood or bone marrow without any associations to presence or absence of histological bone marrow (BM) infiltration by lymphoma cells. With LightCycler® PCR, the numbers of positive cells were higher in samples from patients with BM infiltration of lymphoma cells (1.9 × 10−2) compared to samples from patients without involvement (4.08 × 10−5). A similar trend was seen in samples derived from the peripheral blood. Positivity for t(14;18) after therapy in two patients correlated with clinical relapse 6 months later. The data shown here demonstrate a lower sensitivity of LightCycler® vs. nested PCR for detection of t(14;18). The usefulness of nested PCR for t(14;18) for risk stratification after primary therapy has to be validated in larger trials.
PCR 评估的分子反应是预测惰性滤泡性淋巴瘤无失败生存的最重要因素：MDACC 系列更新。
DOI：
--
发表时间：
2000
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.
影响因子：
--
作者：
Lopez-Guillermo,A;Cabanillas,F;McLaughlin,P;Smith,T;Hagemeister,F;Rodriguez,MA;Romaguera,JE;Younes,A;Sarris,AH;Preti,HA;Pugh,W;Lee,MS
通讯作者：
Lee,MS
通过聚合酶链反应检测 bcl-2 易位残留细胞与 B 细胞淋巴瘤自体骨髓移植后复发风险增加相关。
影响因子：
20.3
作者：
Gribben,JG;Neuberg,D;Freedman,AS;Gimmi,CD;Pesek,KW;Barber,M;Saporito,L;Woo,SD;Coral,F;Spector,N
通讯作者：
Spector,N
惰性滤泡性淋巴瘤分子反应的临床意义。
影响因子：
20.3
作者：
López-Guillermo,A;Cabanillas,F;McLaughlin,P;Smith,T;Hagemeister,F;Rodríguez,MA;Romaguera,JE;Younes,A;Sarris,AH;Preti,HA;Pugh,W;Lee,MS
通讯作者：
Lee,MS